Adlai Nortye Ltd American Depositary Shares (ANL)

$1.50 +0.03 (2.04%)
Market Cap 57.20M
Revenue (ttm) 0.00
Net Income (ttm) -51.87M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 1.03
Volume 846
Avg Vol 19,594
Day's Range N/A - N/A
Shares Out 36.90M
Stochastic %K 21%
Beta -0.83
Analysts Hold
Price Target $9.00

Company Profile

Adlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and development of pharmaceutical products. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trials for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the t...

Industry: Biotechnology
Sector: Healthcare
Phone: 848 230 7430
Address:
Ugland House, PO Box 309, Grand Cayman, Cayman Islands
MilaCraig
MilaCraig Feb. 3 at 8:04 PM
$ANL low float microcap quiet accumulation possible if volume shows
0 · Reply
topstockalerts
topstockalerts Feb. 3 at 7:09 PM
$ANL This one was on watch and now it’s moving 👀. Buyers stepped in right on time. That’s how breakouts start.
0 · Reply
Mantraset3
Mantraset3 Feb. 3 at 6:28 PM
$ANL people love a good $ANL pump
0 · Reply
StockJelli
StockJelli Feb. 3 at 5:35 PM
Update on the midday stock runners. $NPT $CGTL $VELO $ANL $PZG
0 · Reply
GSP
GSP Feb. 3 at 4:47 PM
$ANL started to run right after $GRND news. Coincidence, or a theme? I'll show myself out.
0 · Reply
niko5407
niko5407 Feb. 3 at 4:47 PM
$ANL haha lol
0 · Reply
patb99
patb99 Feb. 3 at 4:43 PM
$ANL 😂
0 · Reply
topstockalerts
topstockalerts Feb. 3 at 4:40 PM
$ANL Impressive strength showing today. Price refuses to pull back. Buyers remain aggressive 🔥.
0 · Reply
patb99
patb99 Feb. 3 at 4:38 PM
$ANL 🧐
0 · Reply
iriestiliess
iriestiliess Feb. 3 at 4:37 PM
$ANL keep on trucking !!
0 · Reply
Latest News on ANL
Adlai Nortye Announces $140.0 Million Private Placement Equity Financing

Feb 3, 2026, 7:00 AM EST - 8 hours ago

Adlai Nortye Announces $140.0 Million Private Placement Equity Financing

Adlai Nortye Enters Exclusive License Agreement with ASK Pharm for Pan-RAS (ON) Inhibitor AN9025 in Greater China

Dec 29, 2025, 6:00 AM EST - 5 weeks ago

Adlai Nortye Enters Exclusive License Agreement with ASK Pharm for Pan-RAS (ON) Inhibitor AN9025 in Greater China

Adlai Nortye to Present Short Talk at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 13, 2025, 11:07 PM EDT - 4 months ago

Adlai Nortye to Present Short Talk at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024

May 23, 2024, 9:03 PM EDT - 1 year ago

Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024

Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy

May 22, 2024, 8:00 AM EDT - 1 year ago

Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy

Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development

Mar 29, 2024, 6:00 AM EDT - 2 years ago

Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development

Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC

Nov 17, 2023, 7:30 AM EST - 2 years ago

Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC

Adlai Nortye Ltd. & Nucleai awarded ESMO 2023 BEST Poster Award

Oct 23, 2023, 8:12 AM EDT - 2 years ago

Adlai Nortye Ltd. & Nucleai awarded ESMO 2023 BEST Poster Award

Adlai Nortye Dives In Nasdaq Debut, As Key Product Faces Hurdles

Oct 13, 2023, 8:00 AM EDT - 2 years ago

Adlai Nortye Dives In Nasdaq Debut, As Key Product Faces Hurdles

Adlai Nortye Ltd. Announces Closing of Initial Public Offering

Oct 3, 2023, 12:05 PM EDT - 2 years ago

Adlai Nortye Ltd. Announces Closing of Initial Public Offering

U.S. IPO Weekly Recap: Holdover Adlai Nortye Leads 4 IPO Week As More Small Deals Enter The Pipeline

Sep 30, 2023, 3:30 AM EDT - 2 years ago

U.S. IPO Weekly Recap: Holdover Adlai Nortye Leads 4 IPO Week As More Small Deals Enter The Pipeline

BIRK KHIW LRE VSME

Adlai Nortye Ltd. Announces Pricing of Initial Public Offering

Sep 29, 2023, 2:46 AM EDT - 2 years ago

Adlai Nortye Ltd. Announces Pricing of Initial Public Offering

U.S. IPO Weekly Recap: August Wraps Up With 1 Nano-Cap

Sep 3, 2023, 10:45 AM EDT - 2 years ago

U.S. IPO Weekly Recap: August Wraps Up With 1 Nano-Cap

ABNB ARM CART IPO IPOS SNOW

U.S. IPO Weekly Recap: IPO Market Sees Fitness, Liquor Marketing, And Medical Devices

Aug 12, 2023, 6:00 AM EDT - 2 years ago

U.S. IPO Weekly Recap: IPO Market Sees Fitness, Liquor Marketing, And Medical Devices

FTEL NRXS NWGL VFS

IPO Update: Adlai Nortye Readies $72 Million U.S. IPO

Aug 11, 2023, 2:16 PM EDT - 2 years ago

IPO Update: Adlai Nortye Readies $72 Million U.S. IPO

Cancer treatment company Adlai Nortye sets terms in IPO

Aug 11, 2023, 7:05 AM EDT - 2 years ago

Cancer treatment company Adlai Nortye sets terms in IPO

Adlai Nortye Ltd. Begins U.S. IPO Rollout

Jul 31, 2023, 6:17 PM EDT - 2 years ago

Adlai Nortye Ltd. Begins U.S. IPO Rollout

MilaCraig
MilaCraig Feb. 3 at 8:04 PM
$ANL low float microcap quiet accumulation possible if volume shows
0 · Reply
topstockalerts
topstockalerts Feb. 3 at 7:09 PM
$ANL This one was on watch and now it’s moving 👀. Buyers stepped in right on time. That’s how breakouts start.
0 · Reply
Mantraset3
Mantraset3 Feb. 3 at 6:28 PM
$ANL people love a good $ANL pump
0 · Reply
StockJelli
StockJelli Feb. 3 at 5:35 PM
Update on the midday stock runners. $NPT $CGTL $VELO $ANL $PZG
0 · Reply
GSP
GSP Feb. 3 at 4:47 PM
$ANL started to run right after $GRND news. Coincidence, or a theme? I'll show myself out.
0 · Reply
niko5407
niko5407 Feb. 3 at 4:47 PM
$ANL haha lol
0 · Reply
patb99
patb99 Feb. 3 at 4:43 PM
$ANL 😂
0 · Reply
topstockalerts
topstockalerts Feb. 3 at 4:40 PM
$ANL Impressive strength showing today. Price refuses to pull back. Buyers remain aggressive 🔥.
0 · Reply
patb99
patb99 Feb. 3 at 4:38 PM
$ANL 🧐
0 · Reply
iriestiliess
iriestiliess Feb. 3 at 4:37 PM
$ANL keep on trucking !!
0 · Reply
AKnewMann
AKnewMann Feb. 3 at 3:56 PM
$ANL who doesn't like ANL?
0 · Reply
StockChasingBags
StockChasingBags Feb. 3 at 3:21 PM
$ANL
0 · Reply
iriestiliess
iriestiliess Feb. 3 at 3:06 PM
$ANL pretty quiet in here
0 · Reply
TheDizPlinTrader
TheDizPlinTrader Feb. 3 at 1:53 PM
$ANL ⛽ 1 Hour Levels Price: $10.07 Support: $9.70 Resistance: $10.70 👉 Tap follow to keep these 1-hour levels on your feed.
0 · Reply
GSP
GSP Feb. 3 at 1:47 PM
Latest gapper list for Tuesday: $ANL $GXAI $AMPX $NNOX .
0 · Reply
OpenOutcrier
OpenOutcrier Feb. 3 at 1:35 PM
$ANL (+8.0% pre) Cancer-drug biotech nets $140M; CEO-linked entities add $55M https://ooc.bz/l/91772
0 · Reply
Steve1961
Steve1961 Feb. 3 at 1:30 PM
$ANL 19 million float
0 · Reply
GSP
GSP Feb. 3 at 1:26 PM
Updated gapper list for today (con't): $ANL $GXAI .
0 · Reply
ricky_lafleur
ricky_lafleur Feb. 3 at 1:19 PM
$ANL Private placement at $6.50. Smart money exited, lent the shares to short, and retail still buying at $10 like it’s a Black Friday deal. This is a financial crime scene.
0 · Reply
Profitrip
Profitrip Feb. 3 at 12:50 PM
$ANL got hit with spread / mover
0 · Reply
Profitrip
Profitrip Feb. 3 at 12:49 PM
$ANL $9.8> dip
0 · Reply
YouVSYou
YouVSYou Feb. 3 at 12:49 PM
12.26 resistance $ANL 13.89 above
0 · Reply